Opendata, web and dolomites

MHT-ImmunoEnhancer SIGNED

Stimuli-Responsive Nanoplatform to Combine Magnetic Hyperthermia with Immunemodulators Delivery for Glioblastoma Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MHT-ImmunoEnhancer project word cloud

Explore the words cloud of the MHT-ImmunoEnhancer project. It provides you a very rough idea of what is the project "MHT-ImmunoEnhancer" about.

immunoenhancer    agent    immunosuppressive    enzymes    glioblastoma    despite    fluorouracil    combine    play    cell    depletion    chemotherapeutic    tumour    ioncs    establishment    survival    recurrence    heating    spreading    myeloid    effect    actions    lethal    tumours    immunosupportive    regression    therapeutic    iron    overcome    microenvironment    mdsc    cpg    consequently    reactivity    therapies    stimuli    superior    enhancement    limit    fu    tme    dual    site    conventional    appears    ed    suppressor    strategy    improvements    stimulus    untreatable    hyperthermal    extremely    therapy    local    induce    hyperthermia    hybrid    suppressive    retention    poor    treatment    prognosis    systemic    polymer    temperature    antitumour    nanocubes    radiotherapy    patient    tolerance    urgent    mht    oligonucleotide    immune    platforms    turn    efficiency    mdscs    human    appropriate    critical    intratumoral    gbm    limited    release    ablation    combination    surgery    context    cells    oxide    ph    inability    magnetic    responsive    cytotoxic    chemotherapy    effectivity    thermal    fever    immunotherapy    damage   

Project "MHT-ImmunoEnhancer" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 183˙473.00

Map

 Project objective

Glioblastoma (GBM) is one of the most lethal and untreatable human tumours, and is characterized by its extremely poor prognosis. Conventional therapies, including surgery, radiotherapy and chemotherapy, have not resulted in major improvements in the survival, due to high recurrence and tumour spreading. Therefore, there is an urgent need to develop new effective therapies to improve patient survival. The establishment of an immunosuppressive tumour microenvironment (TME) in GBM is known to limit the cytotoxic effects of conventional therapies and in this context, myeloid-derived suppressor cells (MDSCs) play a critical role by promoting immune tolerance, tumour growth and spreading. Hyperthermal therapy in GBM has resulted in improved immune reactivity of tumours, despite this, its effectivity has been limited by its inability to overcome the immunosuppressive TME and induce strong systemic antitumour responses. Consequently, targeting MDSCs in combination with thermal ablation therapies appears to be a very promising strategy. The goal of the MHT-ImmunoEnhancer project is the development of a dual stimuli-responsive hybrid polymer/Iron oxide nanocubes (IONCs) delivery system in order to combine local fever-range Magnetic Hyperthermia (MHT) with MDSC depletion-targeted immunotherapy for intratumoral treatment of GBM. The specific objectives of our strategy are, 1) to exploit the superior heating efficiency of the hybrid polymer/IONCs platforms to induce tumour damage. 2) To turn the immunosuppressive TME into an immunosupportive one, by local delivery of CpG oligonucleotide; along with 5-Fluorouracil (5-FU), a chemotherapeutic agent. 3) To release CpG and 5-FU specifically at the tumour site under the appropriate stimulus (pH or enzymes/temperature), thus enhancing their tumour retention and therapeutic effect. All these actions will result in the reduction of T-cell-suppressive activity of MDSCs, enhancement of antitumour immune response and tumour regression.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MHT-IMMUNOENHANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MHT-IMMUNOENHANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CORRELATION (2020)

Characterization and prediction of service-level traffic for future sliced mobile network

Read More  

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

DNANanoProbes (2019)

Design of light-harvesting DNA-nanoprobes with ratiometric signal amplification for fluorescence imaging of live cells.

Read More